Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M. Tamura K, et al. Among authors: negoro s. Cancer Chemother Pharmacol. 2007 Jul;60(2):285-93. doi: 10.1007/s00280-006-0382-7. Epub 2006 Nov 30. Cancer Chemother Pharmacol. 2007. PMID: 17136542 Clinical Trial.
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Kudoh S, et al. Among authors: negoro s. J Clin Oncol. 2006 Aug 1;24(22):3657-63. doi: 10.1200/JCO.2006.06.1044. J Clin Oncol. 2006. PMID: 16877734 Clinical Trial.
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
Masuda N, Negoro S, Hausheer F, Nakagawa K, Matsui K, Kudoh S, Takeda K, Yamamoto N, Yoshimura N, Ohashi Y, Fukuoka M. Masuda N, et al. Among authors: negoro s. Cancer Chemother Pharmacol. 2011 Mar;67(3):533-42. doi: 10.1007/s00280-010-1340-y. Epub 2010 May 15. Cancer Chemother Pharmacol. 2011. PMID: 20473611 Free PMC article. Clinical Trial.
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M. Yoshimura N, et al. Among authors: negoro s. Lung Cancer. 2006 Mar;51(3):363-8. doi: 10.1016/j.lungcan.2005.10.006. Epub 2005 Dec 20. Lung Cancer. 2006. PMID: 16364494 Clinical Trial.
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, Fukuoka M; West Japan Thoracic Oncology Group (WJTOG). Yamamoto N, et al. Among authors: negoro s. Cancer. 2006 Aug 1;107(3):599-605. doi: 10.1002/cncr.22024. Cancer. 2006. PMID: 16804877 Free article. Clinical Trial.
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Saito H, et al. Among authors: negoro s. J Clin Oncol. 2006 Nov 20;24(33):5247-52. doi: 10.1200/JCO.2006.07.1605. J Clin Oncol. 2006. PMID: 17114657 Clinical Trial.
337 results